natgillin/translations-raw huggingface dataset:
In controlled clinical studies, the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
U kontroliranim kliničkim ispitivanjima incidencija zatajenja srca uz liječenje pioglitazonom bila je ista kao i u skupinama liječenim placebom, metforminom i sulfonilurejom, ali povećala se kad je korišten u kombiniranoj terapiji s inzulinom.
Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity.
Slične promjene u distribuciji masnog tkiva u tijelu uz pioglitazon praćene su poboljšanom inzulinskom osjetljivošću.
A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and end-stage renal disease on haemodialysis.
Jednokratna doza od 50 mg alogliptina primijenjena je u 4 skupine bolesnika s različitim stupnjevima oštećenja bubrega (klirens kreatinina (CrCl) prema Cockcroft-Gault formuli): blago (CrCl = > 50 do ≤ 80 ml/min), umjereno (CrCl = ≥ 30 do ≤ 50 ml/min), teško (CrCl = < 30 ml/min) i završni stadij bolesti bubrega na hemodijalizi.
Symptoms of a serious allergic reaction may include; rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing.
Simptomi ozbiljne alergijske reakcije mogu uključivati: osip, izdignute crvene mrlje na koži (koprivnjača), oticanje lica, usnica, jezika i grla što može uzrokovati teškoće pri disanju ili gutanju.
Following oral administration, pioglitazone is rapidly absorbed and peak serum concentrations of unchanged pioglitazone are usually achieved 2 hours after administration.
Nakon peroralne primjene, pioglitazon se brzo apsorbira, a vršne koncentracije neizmijenjenog pioglitazona u plazmi obično se postižu 2 sata nakon primjene.
How to take Incresync
Kako uzimati Incresync
Investigations weight increased common alanine aminotransferase increased not known
Povišena alanin aminotransferaza
Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.
Alogliptin stoga poboljšava kontrolu glikemije putem mehanizma ovisnog o glukozi, pri čemu se pri visokim razinama glukoze pojačava lučenje inzulina i suprimiraju razine glukagona.
Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (< 1% of the parent compound), and N-acetylated alogliptin, M-II (< 6% of the parent compound).
C] alogliptina nađena su dva minorna metabolita, N-demetilirani alogliptin, M-I (<1% izvornog spoja) i N-acetilirani alogliptin, M-II (<6% izvornog spoja).
Therefore, haemodialysis is of little clinical benefit in overdose.
Stoga hemodijaliza kod predoziranja ima mali klinički učinak.
- if you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, glibenclamide) or insulin.
• ako uzimate drugi antidijabetički lijek poznat kao „sulfonilureja“ (npr. glipizid, tolbutamid, glibenklamid) ili inzulin
Due to the increased risk of hypoglycaemia in combination with metformin, a lower dose of metformin or the pioglitazone component may be considered to reduce the risk of hypoglycaemia when this combination is used (see section 4.2).
Zbog povećanog rizika od hipoglikemije u kombinaciji s metforminom, preporučuje se niža doza metformina ili pioglitazona kada se u liječenju primjenjuje ova kombinacija (vidjeti dio 4.2).
• as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance.
• kao dodatak dijeti i tjelovježbi za poboljšanje kontrole glikemije u odraslih bolesnika (posebice onih s prekomjernom tjelesnom težinom) u kojih nije postignuta odgovarajuća kontrola samo pioglitazonom, a u kojih metformin nije prikladan zbog kontraindikacija ili nepodnošljivosti.
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
Ispitivanje kardiovaskularnog ishoda kod primjene pioglitazona provedeno je u bolesnika mlađih od 75 godina sa šećernom bolešću tipa 2 i već postojećom teškom makrovaskularnom bolešću.
• The Prescriber Guide
• Vodič za propisivanje lijeka
You should also discuss with your doctor if you experience the following side effects:
Savjetujte se s liječnikom ako primijetite sljedeće nuspojave:
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical studies with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
U meta-analizi kontroliranih kliničkih ispitivanja s pioglitazonom češće su prijavljeni slučajevi karcinoma mokraćnog mjehura u skupinama koje su primale pioglitazon (19 slučajeva na 12 506 bolesnika, 0,15%) nego u kontrolnim skupinama (7 slučajeva na 10 212 bolesnika, 0,07%) HR=2,64 (95% CI 1,11-6,31, p=0,029).
The recommended dose is one tablet of 25 mg/30 mg or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken.
Preporučena doza je jedna tableta od 25 mg/30 mg ili 25 mg/45 mg jedanput na dan, ovisno o dozi pioglitazona koju bolesnik već uzima.
The following data are findings from studies performed with alogliptin or pioglitazone individually.
Sljedeći podaci su nalazi iz ispitivanja provedenih zasebno s alogliptinom ili pioglitazonom.
In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4).
S obzirom na moguće rizike produljene terapije pioglitazonom, liječnici koji propisuju lijek trebaju i dalje rutinski procjenjivati da je korist liječenja Incresyncom održana (vidjeti dio 4.4).
Common: - Symptoms of low blood sugar (hypoglycaemia) may occur when Incresync is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide).
• Simptomi niskog šećera u krvi (hipoglikemija) mogu se javiti ako se Incresync uzima u kombinaciji s inzulinom ili sulfonilurejama (npr. glipizid, tolbutamid, glibenklamid).
Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session).
Hemodijalizom se mogu ukloniti minimalne količine alogliptina (tijekom 3-satne hemodijalize uklonjeno je približno 7% lijeka).
Alogliptin may, therefore, be administered with or without food.
Alogliptin se, stoga, može primjenjivati s hranom ili bez nje.
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat.
Stvaranje i prisutnost kamenaca u mokraćnom traktu s posljedičnom nadraženošću i hiperplazijom postavila se kao temeljni mehanizam opaženog tumorogenog odgovora u mužjaka štakora.
In animal fertility studies conducted with pioglitazone there was no effect on copulation, impregnation or fertility index.
U ispitivanjima utjecaja na plodnost u životinja nije bilo učinka na kopulaciju, oplodnju ili indeks plodnosti.
Administration of Incresync with food resulted in no change in overall exposure to alogliptin or pioglitazone.
Primjenom lijeka Incresync s hranom nije bilo promjene u ukupnoj izloženosti alogliptinu ili pioglitazonu.
Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy.
Klinički značajna sniženja HbA1c u usporedbi s placebom s 25 mg alogliptina također su opažena bez obzira na to jesu li bolesnici istodobno primali terapiju metforminom ili sulfonilurejom.
Combination treatment with alogliptin and pioglitazone to pregnant rats slightly augmented pioglitazone-related foetal effects of growth retardation and visceral variations, but did not induce embryo-foetal mortality or teratogenicity.
Kombinirano liječenje alogliptinom i pioglitazonom je u skotnih štakora blago potaklo s pioglitazonom povezane učinke na fetalni rast i fetalne visceralne varijacije, ali nije izazvalo embriofetalnu smrtnost ili teratogenost.
Steady-state pharmacokinetics is similar in patients aged 65 years and over and young subjects (see section 4.2).
Farmakokinetika u stanju dinamičke ravnoteže u bolesnika u dobi od 65 ili više godina slična je onoj u mladih ispitanika (vidjeti dio 4.2).
Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4).
Nužan je oprez kada se alogliptin primjenjuje u kombinaciji s metforminom i tiazolidindionom jer je primijećen povećani rizik od hipoglikemije s ovom trojnom terapijom (vidjeti dio 4.4).
• in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
• u kombinaciji s metforminom (tj. trojna kombinirana terapija), kao dodatak dijeti i tjelovježbi, za poboljšanje kontrole glikemije u bolesnika (posebice onih s prekomjernom tjelesnom težinom) u kojih nije postignuta odgovarajuća kontrola maksimalnom podnošljivom dozom metformina i pioglitazona.
Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies.
Alogliptin nije bio genotoksičan u standardnom setu in vitro i in vivo ispitivanja genotoksičnosti.
Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing.
Primjenom 25 mg alogliptina u bolesnika sa šećernom bolešću tipa 2 postignut je maksimum inhibicije DPP-4 unutar 1 do 2 sata koji prelazi 93% i nakon jednokratne doze od 25 mg i nakon 14 dana uzastopne primjene jedanput na dan.
In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively.
U ispitivanju kardiovaskularnih ishoda stope prijavljenih pankreatitisa u bolesnika liječenih alogliptinom ili placebom bile su 3 odnosno 2 događaja na 1000 bolesnik godina.
Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose.
Alogliptin nije bio teratogen u štakora ili kunića pri sistemskoj izloženosti na razini bez opaženih nuspojava koja je daleko iznad izloženosti kod ljudi pri preporučenoj dozi.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8)
• Preosjetljivost na djelatne tvari ili bilo koju od pomoćnih tvari navedenih u dijelu 6.1 ili ozbiljne reakcije preosjetljivosti u anamnezi, uključujući anafilaktičku reakciju, anafilaktički šok i angioedem, na bilo koji drugi inhibitor dipeptidil-peptidaze-4 (DPP-4) (vidjeti dijelove
Nylon/aluminium/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil.
Blisteri od najlon/aluminij/polivinil klorida (PVC) sa protisnom aluminijskom folijom.
Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.
Zatajenje srca bilo je rijetko prijavljeno nakon stavljanja pioglitazona u promet, ali češće kad se pioglitazon primjenjivao u kombinaciji s inzulinom ili u bolesnika sa zatajenjem srca u anamnezi.
Intrinsic clearance is, therefore, reduced coupled with a higher unbound fraction of pioglitazone (see section 4.2).
Intrinzički klirens je stoga smanjen, zajedno s većim udjelom nevezanog pioglitazona (vidjeti dio 4.2).
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations.
Poboljšana kontrola glikemije povezana je sa smanjenjem koncentracija inzulina u plazmi natašte i nakon obroka.
In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2).
U in vitro ispitivanjima nađeno je da alogliptin nije supstrat ni inhibitor ključnih transportera povezanih s dispozicijom lijeka u bubrezima: transportera organskih aniona-1 (OAT-1), transportera organskih aniona-3 (OAT-3) ili transportera organskih kationa-2 (OCT2).
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors.
U razdoblju nakon stavljanja lijeka u promet također su prijavljeni slučajevi perifernog edema i zatajenja srca u bolesnika koji su istodobno uzimali pioglitazon i nesteroidne protuupalne lijekove, uključujući selektivne COX-2 inhibitore.
Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria.
Spontano prijavljene reakcije preosjetljivosti u bolesnika liječenih pioglitazonom nakon stavljanja lijeka u promet uključuju anafilaksiju, angioedem i urtikariju.
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.
U kliničkim ispitivanjima alogliptin nije imao klinički značajan učinak na farmakokinetiku kofeina, (R)-varfarina, pioglitazona, gliburida, tolbutamida, (S)-varfarina, dekstrometorfana, atorvastatina, midazolama, oralnog kontraceptiva (noretindron i etinil estradiol), digoksina, feksofenadina, metformina ili cimetidina, potvrđujući i in vivo dokaz niskog potencijala interakcija sa supstratima CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glikoproteina i OCT2.
In studies performed with the individual active substances, both alogliptin and pioglitazone were excreted in the milk of lactating rats.
U ispitivanjima pojedinačnih djelatnih tvari, i alogliptin i pioglitazon su se izlučivali u mlijeku štakorica u laktaciji.
Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.
Ispitivanja in vitro su pokazala da je alogliptin blagi induktor CYP3A4, međutim ispitivanja in vivo nisu pokazala da alogliptin inducira CYP3A4.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
U ispitivanju u trajanju od 20 tjedana, osim što je snizio trigliceride natašte, pioglitazon je snizio postprandijalnu hipertrigliceridemiju tako što je utjecao na apsorbirane trigliceride i na one sintetizirane u jetri.
A clinical study of alogliptin as add-on therapy to pioglitazone demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo.
U kliničkim ispitivanjima alogliptina kao dodatka terapiji pioglitazonom nije bilo klinički značajnog povećanja stope hipoglikemije u usporedbi s placebom.
The decision whether to continue the patient on therapy with Incresync should be guided by clinical judgement pending laboratory evaluations.
Odluku o nastavku terapije Incresyncom treba donijeti na temelju kliničke procjene ovisno o laboratorijskim nalazima.
In clinical studies of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide.
U kliničkim ispitivanjima u trajanju do dvije godine, pioglitazon je snizio ukupne trigliceride u plazmi i slobodne masne kiseline te povisio razine HDL-kolesterola u usporedbi s placebom, metforminom i gliklazidom.
No studies in lactating animals have been conducted with the combined active substances of Incresync.
Nisu provedena ispitivanja na životinjama u laktaciji s kombiniranim djelatnim tvarima Incresynca.
In most clinical studies, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo with small, but not clinically significant, increases in LDL-cholesterol levels.
U većini kliničkih ispitivanja primijećeno je sniženje ukupnih triglicerida i slobodnih masnih kiselina u plazmi te povišenje razine HDL-kolesterola u usporedbi s placebom, uz mala ali ne i klinički značajna povišenja razina LDL-kolesterola.
Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.
C] alogliptina, 76% ukupne radioaktivnosti eliminirano je mokraćom, a 13% stolicom.
Tlf: +47 6676 3030 infonorge@takeda.com
Tlf: +47 6676 3030 infonorge@nycomed.no
In combination studies, pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg.
Dodavanje pioglitazona metforminu u ispitivanjima kombinacija rezultiralo je povećanjem srednje vrijednosti težine tijekom jedne godine za 1,5 kg, a dodavanje sulfonilureji za 2,8 kg.
What Incresync is used for
Za što se Incresync koristi
No environmental impact is anticipated from the clinical use of pioglitazone.
Ne očekuje se utjecaj na okoliš tijekom kliničke primjene pioglitazona.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator.
Prijelomi su opaženi u 2,6% žena koje su uzimale pioglitazon u usporedbi sa 1,7% žena liječenih usporednim lijekom.
When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.
Ako se koncentracije glukoze 4 sata nakon obroka preračunaju na prosječnu vrijednost doručka, ručka i večere, 14 dana liječenja s 25 mg alogliptina dovodi do srednje vrijednosti sniženja razine glukoze koja nakon korekcije na temelju placeba iznosi -35,2 mg/dl u odnosu na početnu vrijednost.
Studies in animal models of diabetes showed that concomitant treatment with alogliptin and pioglitazone produced both additive and synergistic improvements in glycaemic control, increased pancreatic insulin content and normalised pancreatic beta-cell distribution.
Ispitivanja šećerne bolesti na životinjskim modelima pokazala su da istodobno liječenje alogliptinom i pioglitazonom dodatno i sinergistički poboljšava kontrolu glikemije, povisuje sadržaj inzulina u gušterači i normalizira distribuciju beta-stanica u gušterači.
In clinical studies with pioglitazone, the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
U kliničkim ispitivanjima pioglitazona, incidencija povišenja ALT-a za više od tri puta iznad gornje granice normale bila je jednaka onoj za placebo, ali manja od one viđene u skupinama koje su kao usporedni lijek primale metformin ili sulfonilureju.
Due to its pioglitazone component, Incresync should not be used in patients with hepatic impairment (see section 4.2).
Zbog sadržanog pioglitazona, Incresync se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dio 4.2).
Adults (≥ 18 years old) The dose should be individualised on the basis of the patient's current treatment regimen
Dozu Incresynca treba individualno odrediti na temelju trenutnog režima liječenja svakog bolesnika.
In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.
U skupinama koje su primale usporedni lijek, dodavanje sulfonilureje metforminu rezultiralo je povećanjem srednje vrijednosti težine za 1,3 kg, a dodavanje metformina sulfonilureji smanjenjem težine za 1,0 kg.
Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin.
Primjenom uz obrok s visokim sadržajem masti nije bilo promjene u ukupnoj i vršnoj izloženosti alogliptinu.
This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint.
To je potvrđeno klinički i statistički značajnim sniženjima glikoziliranog hemoglobina (HbA1c) i glukoze u plazmi natašte u usporedbi s kontrolnom skupinom od početne vrijednosti do ishoda ispitivanja.
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away.
Ako uzmete više tableta nego što ste trebali, ili ako netko drugi ili dijete uzme
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.
Pri uključivanju u ispitivanje bolesnici su imali u prosjeku 61 godinu, prosječno trajanje dijabetesa 9,2 godina i prosječni HbA1c od 8,0%.
Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin.
Rezultati kliničkih ispitivanja interakcija također pokazuju da nema klinički značajnih učinaka gemfibrozila (inhibitor CYP2C8/9), flukonazola (inhibitor CYP2C9), ketokonazola (inhibitor CYP3A4), ciklosporina (inhibitor p-glikoproteina), vogliboze (inhibitore alfa-glukozidaze), digoksina, metformina, cimetidina, pioglitazona ili atrovastatina na farmakokinetiku alogliptina.
No dose adjustment is necessary (see section 4.2).
Prilagodba doze nije potrebna (vidjeti dio 4.2).
Swallow your tablet(s) whole with water.
Tabletu progutajte cijelu s vodom.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin.
Ispitivanja interakcija pokazala su da pioglitazon nema značajnog učinka na farmakokinetiku niti na farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients ≥ 65 years old treated with 25 mg alogliptin (3.8%) to that in patients < 65 years old (3.6%).
U analizi objedinjenih podataka iz 12 ispitivanja, ukupna incidencija svih epizoda hipoglikemije bila je u bolesnika u dobi od ≥ 65 godina starosti liječenih s 25 mg alogliptina (3,8%) slična kao i u onih < 65 godina starosti (3,6%).
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose.
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.